| Oct 30 |
Eterna Therapeutics Completes Strategic Financial Restructuring with the Aim to Accelerate its Developmental Activities and Long-Term Success
|
| Oct 18 |
Eterna, Factor announce license, collaboration agreement
|
| Oct 17 |
Eterna Therapeutics and Factor Bioscience Announce Exclusive License and Collaboration Agreement to Accelerate Cell Therapy Development for Oncology, Autoimmune, and Rare Diseases
|
| May 8 |
Eterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory Board
|
| May 7 |
Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on the Development of a mRNA-Engineered iPSC Line which Mimics Native B2M Expression, via Targeted Insertion of HLA-E at the B2M Locus
|
| May 7 |
Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MS...
|
